Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
McGuire P. et al, (2018), American Journal of Psychiatry, 175, 225 - 231
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
Devinsky O. et al, (2014), Epilepsia, 55, 791 - 802
Cannabinoids and schizophrenia: therapeutic prospects.
Robson PJ. et al, (2014), Curr Pharm Des, 20, 2194 - 2204
Therapeutic potential of cannabinoid medicines
Robson PJ., (2014), Drug Testing and Analysis, 6, 24 - 30
Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine
Robson P., (2011), Expert Opinion on Drug Safety, 10, 675 - 685
Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis-Based Medicine
Russo EB. et al, (2007), ChemInform, 38
The effects of low doses of delta-9 tetrahydrocannabinol on reinforcement processing in the risky decision-making of young healthy adults.
Rogers RD. et al, (2007), Neuropsychopharmacology, 32, 417 - 428
Effect of sublingual application of cannabinoids on intraocular pressure: A pilot study
Tomida I. et al, (2006), JOURNAL OF GLAUCOMA, 15, 349 - 353
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
Wade DT. et al, (2006), Multiple Sclerosis Journal, 12, 639 - 645
Safety and tolerability of long-term treatment with a cannabis-based medicine (SATIVEX) in patients with rheumatoid arthritis
Blake DR. et al, (2006), ANNALS OF THE RHEUMATIC DISEASES, 65, 498 - 498
Low doses of delta-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, healthy adults.
Makela P. et al, (2006), Neuropsychopharmacology, 31, 462 - 470
Beyond the end of the line: Case reports of conversion from dextromoramide to other opiates within addiction maintenance treatment
Strang J. et al, (2006), Drugs: Education, Prevention and Policy, 13, 473 - 480
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
Wade DT. et al, (2004), Multiple Sclerosis Journal, 10, 434 - 441
Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults.
Nicholson AN. et al, (2004), J Clin Psychopharmacol, 24, 305 - 313
A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215)
Guy GW. and Robson PJ., (2004), Journal of Cannabis Therapeutics, 3, 121 - 152
A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of CBME per Oral in Healthy Male and Female Volunteers (GWPK0112)
Guy GW. and Robson PJ., (2004), Journal of Cannabis Therapeutics, 3, 79 - 120
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms
Wade DT. et al, (2003), Clinical Rehabilitation, 17, 21 - 29
Prospects for New Cannabis-Based Prescription Medicines
Whittle BA. et al, (2001), Journal of Cannabis Therapeutics, 1, 183 - 205
Therapeutic aspects of cannabis and cannabinoids
Robson P., (2001), British Journal of Psychiatry, 178, 107 - 115
Patients attending a new drug clinic in 1990 and 1995: characteristics and outcome
Noble F. and Robson PJ., (2000), JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 6, 71 - 74